Project Grant R01HL163419
Award Date
8/15/24
Completion Date
5/31/29
Dollars Obligated
$1.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40202, USA
Similar Awards
This Cooperative Agreement award of $2,529,292.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a randomized clinical trial to evaluate two interventions for improving mobility in patients with peripheral artery disease (PAD) who have undergone lower extremity revascularization. The primary aims are to determine if: 1) home-based exercise combined with revascularization improves 6-minute walk distance more than revascularization alone,...
This federal Project Grant award, with a total funding amount of $153,252, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support a 3-year research program focused on elucidating the molecular mechanisms and clinical significance of a specific macrophage population (SPP1+ macrophages) in peripheral arterial disease (PAD). The primary objectives are to determine if SPP1+ macrophages inhibit...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $687,517 to the University of Alabama at Birmingham to investigate the role of the protein Leiomodin1 (LMOD1) in the formation of mature blood vessels, which is critical for treating peripheral artery disease (PAD). The research aims to elucidate the mechanistic pathway by which reduced LMOD1 leads to impaired blood vessel maturation, determine if this...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $761,042 to the University of Pittsburgh to conduct research on the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The key objectives are to define how the DNA damage response suppresses CD73 levels, and how reduced CD73-mediated adenosine production alters arginine methylation to promote osteogenic gene transcription in...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,220,496 Cooperative Agreement under the Cardiovascular Diseases Research (CFDA 93.837) program to Duke University to conduct the U.S. portion of the multinational LEADER-PAD clinical trial. The trial will enroll 1,000 U.S. participants out of a planned 6,150 participants globally to assess whether low-dose colchicine can reduce the risk of cardiovascular and limb-related outcomes in patients with peripheral artery disease...
This Project Grant award for $691,708.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports the development of a novel contrast-free ultrasound-based quantitative angio flow imaging technique to assess peripheral arterial disease (PAD) of the lower limbs. The research project aims to determine the efficacy of this new "Angio Flow Reactivity Analysis" (AFRA) method for assessing PAD in patient...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $528,179 to the University of Miami to investigate reprogramming of bone marrow-derived monocytes as a novel strategy to improve neovascularization and outcomes in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effect of ischemia training on monocyte reprogramming; 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,408,580 to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary objective is to investigate whether activating this pathway can restore contractile function in human induced pluripotent stem cell cardiomyocytes with DCM-causing mutations, and whether it can mitigate clinical...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $633,045 to the University of Pittsburgh to investigate the pathogenic mechanisms and therapeutic approaches for exercise intolerance in patients with Post-Acute Sequelae of COVID-19 (PASC). The key objectives are to: 1) Evaluate the predictive value of plasma angiotensin-converting enzyme 2 (ACE2) activity as a biomarker for exercise capacity in PASC patients...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $445,500 supports research to define the mechanisms by which platelets may regulate monocyte/macrophage interactions at the site of abdominal aortic aneurysm (AAA) injury, with the goal of developing new tools to promote tissue regeneration and healing of cardiovascular damaged tissues. The research aims to provide a blueprint for site-specific regeneration and healing of AAAs, which...